Novo Nordisk and Pfizer Stocks Today (Nov. 10, 2025): Pfizer Clinches $10B Metsera Deal as Novo Rises on Exit and India Brand Move
Published: November 10, 2025 Summary: On Monday, Pfizer said it will acquire obesity‑drug developer Metsera in a deal worth up to $10 billion, while Novo Nordisk shares climbed after bowing out of the bidding war. Governance drama around Novo’s board intensified as Norway’s $1.5 trillion sovereign wealth fund said it would abstain from key votes this week. Separately, Novo struck a distribution pact in India to sell a new branded version of its semaglutide weight‑loss shot. Reuters+3Reuters+3Reuters+3 Key takeaways How NVO and PFE are trading today Pfizer seals Metsera deal: what’s in it and why it matters Pfizer’s agreement to